There are mainly two types of short RNAs that target complementary messengers in animals: small interfering RNAs and microRNAs. Both are produced by the cleavage of double-stranded RNA precursors by Dicer, a member of the Rnase III family of doublestranded specific endonucleases, and both guide the RNA-induced silencing complex to cleave specifically RNAs sharing sequence identity with them. In designing a particular RNA interference (RNAi), it is important to identify the sense/antisense combination that provides the most potent suppression of the target mRNA, and several rules have been established to give 490% gene expression inhibition. RNAi technology can be directed against cancer using a variety of strategies. These include the inhibition of overexpressed oncogenes, blocking cell division by interfering with cyclin E and related genes or promoting apoptosis by suppressing antiapoptotic genes. RNAi against multidrug resistance genes or chemoresistance targets may also provide useful cancer treatments. Studies investigating these approaches in preclinical models are also reviewed.
R
NA interference (RNAi) refers to a group of related gene-silencing mechanisms in which the terminal effector molecule is a short antisense RNA. In nature, several main functions have been associated to RNAi, among those being the control of developmental processes, the defense from parasitic nucleic acids and heterochromatic silencing. RNAi is also a powerful tool to silence gene expression in a sequence-specific manner. The phenomenon was first recognized in transgenic plants, when trying to increase flower pigmentation in petunias, by the addition of chalcone synthase 1 or flavonoid genes. 2 However, the plants developed variegated petals and in some instances petals with total absence of color. Therefore, the exogenous transgene was, in some way, affecting the expression of endogenous genes in trans. The term RNAi was first used in the worm Caenorhabditis elegans to explain that dsRNA complementary to a particular gene was more efficient at silencing the corresponding gene expression than either strand individually. 3 Subsequent studies indicated that silencing correlated with the processing of dsRNA to small 21-23 nucleotide-duplex short-interfering RNAs (siRNAs) 4 and that a dsRNA-specific endoribonuclease III, known as Dicer, was responsible for processing dsRNA to siRNAs. 5 The discovery and characterization of RNAi is providing us with a new tool for targeted inhibition of gene expression in many different fronts. This work is not intended to give a comprehensive review of the antisense world, but rather to focus on what we know about the mechanism and function of RNAi, and how this molecule can best be applied as a therapy against cancer.
Biogenesis, mechanism and function of siRNAs
There is a general model for RNAi (Fig 1a) by which a long dsRNA is first recognized and cleaved by Dicer to siRNAs, which are subsequently incorporated into an RNA-induced silencing complex (RISC). There is a strict requirement for siRNA to be 5 0 phosphorylated to enter RISC, 6 and thus when siRNA lacks this 5 0 phosphate, it is rapidly phosphorylated by an endogenous kinase. 7 The duplex siRNA is unwound by an ATP-dependent RNA helicase, leaving the antisense strand exposed to guide RISC to its homologous target mRNA for endonucleolitic cleavage. The target mRNA is cleaved at a single site in the center of the duplex region between the guide siRNA and the target mRNA, 10 nt from the 5 0 -end of siRNA; 8 further mRNA degradation by endo-and exonucleases follows.
So far, endogenously expressed siRNAs have not been found in mammals, but could be generated from sense and antisense genomic transcripts, or perhaps from the activity of a cellular RNA-dependent RNA polymerase (found in plants, 9 fungi, 10 and nematodes, 11 but not in flies or mammals), or as an intermediate of viral replication. 12 A second type of siRNAs are the related micro-RNAs (miRNAs), which have been identified, cloned and characterized from various organisms and cell types. [13] [14] [15] This type of tiny RNAs is an endogenous, noncoding proteins, B22 nt in length, and plays an important regulatory role in a wide range of organisms, from plants 16 to mammals, 17 targeting mRNAs for cleavage or translational repression (Fig 1b) . Close to 200 genes have been mapped representing known or predicted miRNAs in the human genome. 18 Some miRNA genes reside in introns and are likely to share regulation sequences and primary transcript with their pre-mRNA host genes. Other miRNA genes, presumably transcribed from their own promoters, are clustered and transcribed as long precursors (more than 1 kb long). 13 Both types are thus probably, but maybe not exclusively, transcribed by pol II as opposed to the short typical pol III transcripts. The first step in miRNA maturation is the nuclear cleavage preformed by the Drosha RNase III endonuclease to give a B60-70 nt stem loop intermediate, having a 5 0 phosphate and B2 nt 3 0 overhang. 19 This pre-miRNA is actively transported from the nucleus to the cytoplasm by Ran-GTP and the export receptor Exportin-5. 20, 21 The nuclear cut by Drosha 22 defines one end of the mature miRNA, and the other is processed in the cytoplasm by Dicer, which recognizes the double-stranded portion of the pre-miRNA and cuts about two helical turns away from the base of the stem loop. This eliminates the loop itself and leaves the 5 0 phosphate and B2 nt 3 0 overhang characteristic of the RNase III products. The existence of a transient miRNA duplex is supported by its cloning in nematodes and flies. According to this model, the first cleavage by Drosha determines the specificity of both ends, and Dicer only chops up an RNA double strand, irrespective of its sequence. [23] [24] [25] The determinants of Drosha recognition are not well characterized, but include the secondary structure of the base of the primary stem loop as well as some elements flanking the stem loop, but generally within 125 nt of miRNA. 22, 26 What we have now is a mature miRNA, and siRNA-like imperfect duplex ready for RISC. Once loaded on RISC, there is no substantial difference between miRNA and siRNA toward the target messenger RNA. 27 Both of them are capable of undertaking two possible post-transcriptional mechanisms: mRNA cleavage, translational repression (Fig 2a and b) . The choice is determined by the degree of complementarity with the target. A total identity between siRNA or miRNA and mRNA will specify cleavage, while partial complementarity of any of the two RNAs in the 3 0 -untranslatable (3 0 -UTR) region of the messenger will induce translational repression. 15, 28 Transcriptional heterochromatic silencing, a third possibility observed in Drosophila 29 and Schizosaccharomyces pombe, 30 is attributed mainly to siRNAs (Fig 2c) . Despite these general rules, there is a plant miRNA, miR172, which appears to regulate APETALA2 via translational repression, and The distinction between siRNAs and miRNAs is subtle 15 (Fig 1) . They share several steps in biogenesis and can perform interchangeable biochemical functions (Fig 2) . These two types of silencing RNAs cannot be distinguished by their chemical composition or mechanism of action, but they have a different origin, maturation process, evolutionary conservation and gene targets. Whereas siRNAs often derive from viruses, 12, [32] [33] [34] transposons, heterochromatic DNA 29, 30 or mRNAs, miRNA comes mainly from genomic loci distinct from other genes (clustered) or from introns. In the maturation process, siRNAs are processed from long bimolecular RNA duplexes and several siRNAs can be generated from a single precursor molecule; miRNA primary transcripts, on the other hand, form hairpin structures and only one mature molecule is formed from each precursor. Humans and C. elegans encode only one Dicer, which can process both dsRNAi precursors to give siRNA or miRNA, but Drosophila has two (Dcr-1 and Dcr-2), showing a clear division of labor: while Dcr-2 is the major siRNAproducing enzyme, Dcr-1 is vital in miRNA-triggered gene silencing. 35 A similar situation likely exists in Arabidopsis where mutation of the Dcr-1 homolog, DCL1, impairs miRNA but not siRNA production. 36 This separation of function, however, at least in Drosophila, is not absolute because Dcr-1 is also certainly required for efficient RNAi. Dcr-2 (complexed to its associated protein R2D2), on the other hand, appears to have a second function downstream of siRNA formation: assembling itself into RISC along with the siRNA. 37 In relation to evolutionary conservation, endogenous siRNAs are rarely conserved while miRNAs are nearly always very similar in related organisms. 16 Finally, siRNAs tend to silence the same locus (or very similar) from which they originate (homolocus silencing), whereas miRNAs tend to act over very different genes (heterolocus silencing). Examples of homolocus silencing are repression of Tc1 transposons in the germ line of C. elegans 38 or the heterochromatic silencing of tandem repeats of the Drosophila white transgene. 29 Examples of heterolocus silencing include the regulatory lin-4 or let-7 miRNAs, which control the timing of larval development in the nematode C. elegans; 39 bantam, which regulates tissue growth by stimulating cell proliferation and preventing apoptosis in Drosophila;
40 and miR-181, which controls mouse hematopoiesis. 17 A natural consequence from this last difference is that a mutational event in the siRNA coding DNA would also change the target RNA, and the whole process would be preserved, while a mutation in an miRNA coding gene would not be accompanied by a simultaneous compensatory change at the loci of its targets. 15 There are indications that miRNAs might be a class of genes involved in human tumorigenesis. A systematic search for the identification of possible correlations between the genomic position of miRNA genes and cancer-associated regions revealed that 52% of miRNA genes are in cancer-associated genomic regions or in fragile sites. 41 The identification of the corresponding targets has not yet been accomplished.
Two putative new classes of short RNAs have been recently described. [42] [43] [44] The first one was found in C. elegans and encloses 20-22 nucleotide long nonprotein-coding RNAs. 42 Unlike miRNAs, they do not appear to be processed from hairpins since no highly complementary sequences were found nearby in the genome, and furthermore their sequences are not commonly conserved among related species. Although their functions are unknown, many are complementary to mRNAs and might target them for degradation. The second one is a small, nonprotein-coding, 20 nucleotides long doublestranded RNA, called small modulatory RNA (smRNA) and is isolated from mouse neural stem cells. 43 This RNA was identified as a functional transcriptional activator of neuron-specific genes in neuronal cells and is also critical in neuronal differentiation. The mechanism of action appears to be mediated by interaction of the smRNA with a regulatory protein.
Design of the artificial DNAs and vectors for efficient delivery into mammalian cells
In mammalian cells, we can trigger an RNAi response by artificial 21-bp siRNAs, which can cause strong, but transient, inhibition of gene expression. Also, Figure 2 The actions of small silencing RNAs: (a) siRNAs or miRNAs can cleave target mRNAs when complementarity is total; RISC is reused to cleave many molecules of target mRNAs. (b) Translational repression can also be specified by both siRNAs and miRNAs by stalling all of the ribosomes on the message. (c) Transcriptional silencing is mediated by heterochromatic siRNAs and histone methylation.
The use of RNAi against cancer M Izquierdo vector-expressed short hairpin RNAs (shRNAs) can destroy a particular mRNA over prolonged periods. While the first type of molecules mimic the small RNAs processed from long double-stranded regions, the second imitate miRNAs. It is now possible to reduce a target mRNA by 490%, but achieving this goal often requires screening of many siRNAs before truly effective inhibitors are discovered. The selection of the best target site is often difficult, because there are many parameters that can contribute to the highly efficient inhibition of mRNA.
Rules
Synthetic dsRNAs longer than 30 nt will induce in mammals a potent cytokine-based antiviral reaction: the interferon response. This will ultimately lead to a nonspecific degradation of RNA transcripts and a general shutdown of host cell protein translation. Shorter, 21-bp siRNAs could also trigger the antiviral effect. 45, 46 A simple precaution to limit the risk of inducing an interferon response is to use the lowest effective dose, but for cancer therapies, it might be beneficial to induce interferon despite the fact that many commonly used tumor cells have cancer-specific mutations in gene products of the interferon pathway. 47 There are some general and some specific rules to design an efficient siRNA (also enter: http://www.oligoengine.com or http://www.ambion.com). In general, secondary structures in mRNA with tight stem loops should be avoided; 48 no inverted repeats are allowed in the siRNA sequence, and this should share minimal identity with other genes (an NCBI BLAST search can be made at site: http://www.ncbi.nlm.nih.gov/BLAST/). siRNA being a double-stranded molecule, it is important to force RISC to be preferentially loaded with the strand complementary to mRNA (antisense). This can be achieved because RISC will preferentially accept the strand with less stable 5 0 -end, 49, 50 that is, richer in A/U base pairs (Fig 3) . The overall efficiency of the artificial siRNA or shRNA will depend upon additional characteristics: low G/C content (30-60%); beginning with a G or C residue after an AA dimer in the 5 0 -flanking sequence; sense strand base preferences at positions 3 (A), 10 (U), 13 (A) and 19 (A); lack of four or more consecutive T or A to avoid premature pol III transcription termination signals. 51, 52 Negative controls can be made by changing several important positions in the artificial siRNA or using 2 0 -Omethyl oligoribonucleotides in the synthetic siRNA, because that specifically inactivates the siRNA-protein complexes in human cell extracts and cultured human cells. 53 Also, several plant virus-encoded suppressors of RNAi have been identified, and among those the P19 protein of Tomato bushy stunt virus binds and suppresses siRNA in Hela cells. 54, 55 When the target protein is part of a known pathway, it is possible to measure the lack of activity in associated members of the chain.
Vectors
Transient interference can be efficiently achieved by synthetic, double-stranded siRNA transfected to mammalian cells via cationic liposomes. 56 The defense interferon system against viruses, however, is very sensitive to the presence of double-stranded RNA, and under certain conditions, siRNA can activate the interferon system complicating the interpretation of RNA inhibition experiments. The removal of the 5 0 -triphosphate end when siRNA is synthesized in vitro using phage T7 RNA polymerase, instead of chemical methods, is important to avoid the interferon response in mammalian cells. 57 High doses should also be avoided because they will again induce interferon in vivo and in some instances may cause unexpected and divergent changes in the levels of untargeted proteins. 58 Changes in unrelated proteins, however, are not always abolished by titration of siRNA down to almost inefficient levels. 59 High production costs also limits this technology's utility for many laboratories. As an alternative, several DNA-based plasmid vectors for transient and stable expression have been developed. 60, 61 These vectors direct the transcription of shRNAs (Fig 3) from a polymerase-III (H1 or U6)-RNA gene promoter. Alternatively, there are vectors that express long dsRNAs from an RNA polymerase-II promoter, and that have at least in one case avoided the interferon response because the transcript lacked the 5 0 -cap structure and the polyadenylation signal. 62 Although these vectors provide certain advantages over chemically synthesized siRNAs, numerous disadvantages remain, including low and variable transfection efficiency and difficulties of integrating into the host DNA to become stable. Retroviral shRNAs delivery systems based on the mouse Moloney leukemia virus has also been developed. 63, 64 Retroviruses are very efficient, entering a wide range of hosts, including human cells, and will only integrate into replicating cells, providing a very useful characteristic to target neoplastic cells. The main drawback of retroviruses as vectors is the low titers produced by the retroviral packaging cells (B10 6 colony forming units per milliliter of culture), aggravated by the lack of a good and reproducible system to concentrate viral particles. 65 Adenovirus Ad5 can be considered the main alternative to retrovirus. Having dsDNA as their genome, titers of the order of 5 Â 10 10 infective units are not difficult to obtain, but adenoviruses as vectors are not free from problems: the genome size is too large to manipulate easily (36 kb) and they do not distinguish between quiescent and dividing cells. This last characteristic could be circumvented in the case of cancer by choosing as targets genes that are only active in dividing cells. Also of great interest are the conditionally 67 using shRNAs in CRAds, it has been possible to silence up to 70% of the luciferase gene previously inserted in several cancer cell lines. 68 Both lentivirus-and adeno-associated viruses have also been used successfully to deliver viralmediated siRNAs to transgenic mice 69 and the brain. 70, 71 However, none of the two vectors are particularly good for cancer therapies -the first one because it infects both dividing and quiescent cells, and the second because it needs the help of an adenovirus (or Herpes), and because the titers, when modified to become a vector, are considerably low (B10 5 ). A major difficulty in advancing gene therapy technology from the laboratory to the clinic is still linked to discovering or creating a vector system easy to be administered locally, orally or intravenously being able to transduce only neoplastic cells, and efficiently expressing its siRNA against a pathway-key-oncogene.
siRNA in cancer therapeutic models
So far, the most successful strategies against cancer have been the destructive ones. At the cellular level, this implies the elimination, as selectively as possible, of the neoplastic cells. However, not all oncogenes and oncosuppressors contribute equally to cancer development. The plasticity of the cell with a network of signal-transducing pathways makes it difficult to pinpoint the key genes whose blockage would irreversibly lead to self-destruction. RNAi technology can help to discover genes essential for viability in cancer cells that can be then used as targets for suicide. Inhibiting overexpressed oncogenes, such as ras or myc, should block pathways that cancer cells depend on. In most cancers, however, it may be necessary to block pathways at several points, or even to target several pathways. Identifying the genes that are altered in the stepwise progression to malignancy has become one of the central goals of cancer research; automation of data generation (robotics) and computer analysis (bioinformatics) have significantly accelerated the process of discovering cancer-linked genes. Once an oncogene that is highly represented in a particular type of cancer (melanoma or glioblastoma, for example) is identified, there is the hope that this will lead to clinically useful targeted therapies.
One of the most important signaling pathways to control growth and proliferation of our cells is the mitogen-activated protein kinase (MAPK) pathway (Fig  4) . Ras is mutated to an oncogenic form in about 15% of human cancer; stable suppression of tumorigenicity was achieved by virus-mediated RNAi to inhibit specifically the oncogenic allele of K-ras (K-ras V12 ) in human tumor cells. 63 Three more papers [72] [73] [74] have recently reported the use of siRNA to block further the Ras-Raf-Mek-ErkMap kinase cascade, one at the Raf level, and the other one through NADPH oxidase1 (Nox1). The three Raf genes (A-raf, B-raf and C-raf) code for cytoplasmic serine/ threonine kinases that are regulated by binding Ras. Raf proteins phosphorylate Mek 1/2, which in turn phosphorylate Erk 1/2 and these act upon MAPK. Melanoma, on the other hand, is an aggressive skin cancer derived from melanocytes resistant to most current treatments once cells have spread to other parts of the body. The oncogene B-raf was found to be mutated in 59% of melanoma cell lines, in 80% of short-term melanoma cell cultures and 66% of uncultured melanomas, 75 making it a putative Figure 4 The Ras-Raf-Mek-Erk-Map kinase signal transduction pathway through which growth factors can activate a tyrosine kinase receptor; this phosphorylates the membrane-associated SH2 domain-containing adapter GRB (growth factor-bound protein), making it a docking site for the GTP/GDP exchange factor SOS (named after the Drosophila homolog protein called son of sevenless). SOS converts Ras-GDP to Ras-GTP, and this in turn activates Raf and the downstream cascade of enzymes, which culminates in the production of transcription factors. Nox1, indirectly stimulated by Ras, generates ROS that perturbs the growth control contributing to cell transformation. 76 was not long ago clinically evaluated in patients with a variety of malignancies, including melanoma. However, the identification of ras mutations over 20 years ago has not yet led to clinically useful Ras-targeted therapies. Also, RNAi was used to silence the nox1 gene, 74 helping in the understanding of how Ras activates the reactive oxygen species (ROS) and how Nox1 perturbs growth control resulting in malignant transformation (Fig 4) . Depletion of Nox1 prevented Ras-induced transformation, suggesting the possibility of using anti-Nox molecules as neoplastic targets (Table 1 ). The oncogene her2/neu (erbB-2) is overexpressed in 30% of breast and ovarian cancers. A link between the fatty acid synthase (FAS) and her2 was recently identified by using siRNA against FAS mRNA, Her2 or both. siRNA inhibition of FAS negatively regulates the overexpression of her2 at the transcriptional level. Simultaneous targeting of FAS and Her2 by siRNA synergistically downregulated oncoprotein p185
her2 and inhibited tumor cell proliferation by promoting apoptosis. 77 It is suggested that Her could be a molecular sensor of the energy imbalance that participates actively in the maintenance of an abnormally elevated endogenous fatty acid metabolism in cancer cells. FAS could thus be used as a therapeutic target in Her2-overexpressing carcinomas (Table 1) .
RNAi can be directed against cell-cycle control genes to block cell division and promote apoptosis. Cyclin E is required for progression through the G1 phase, and its depletion would lead to G1/S transition arrest. siRNAs have been successfully directed against the messengers of this protein. 78 Later in the cell cycle, the chromosomal kinetochore protein Hec1 (highly expressed in cancer) has a prominent role in spindle checkpoint, and could be considered a good target for causing catastrophic mitotic exit at the M phase 79, 80 (Table 1) . Another example of a good target is Gp210, an integral membrane protein of nuclear pore complexes, essential for proper communication between the nucleus and the cytoplasm. siRNA directed against Gp210 was used to study nuclear membrane structures in Hela cells. 81 It was found that the treatment was lethal for over 60% of the cells within 5 days, and the conclusion that Gp210 was essential for the viability of dividing cells followed.
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors in the digestive tract and a great majority of them have oncogenic kit gene mutations. Kit encodes a growth factor receptor with liganddependent tyrosine kinase activity. Ligand binding triggers receptor dimerization, activation of kinase activity and autophosphorylation. Subsequently, Kit activates several signaling cascades leading to cell proliferation, and cell survival among other cellular responses. 82 Kit inhibition by imatinib mesylate (STI571, Gleevec s ) has been effective therapeutically in patients with GIST. 83 Inhibition is based on the specific occupation of the kinase pocket of the enzyme, blocking access of ATP and consequently preventing phosphorylation of cellular substrates. However, GISTs can develop resistance to imatinib and complete responses are rare when the drug is used on its own. Hence, alternative therapeutic strategies are needed and one of those could be RNAi. Imatinib mesylate also targets the bcr/abl tyrosine kinase resulting from a reciprocal translocation between chromosomes 9 and 22 (Philadelphia chromosome), responsible for chronic myeloid leukemia. In this case, breakpoint-specific siRNAs have decreased Bcr/Abl protein expression and its activity. 84, 85 One way to counteract the resistance that may develop to chemotherapeutic drugs is by suppressing the multidrug transporter MDR1, which has a major role in multidrug resistance. siRNAs against MDR1 overcame such resistance in The use of RNAi against cancer M Izquierdo pancreatic and gastric carcinomas in vitro by up to 91% at the mRNA and protein levels, and decreased resistance to daunorubicin to 89 and 58% in these cancers, respectively. 86 Chemoresistance to gemcitabine is also a major cause of pancreatic adenocarcinoma treatment failure. siRNAs targeting the M2 subunit of ribonucleotide reductase exhibited therapeutic synergism with gemcitabine, resulting in tumor growth retardation and tumor mass reduction by 87%, and absence of hepatic metastasis in the nude mouse xenograft model. 87 Increased resistance to apoptosis often characterizes cancer cells. This property enables them to survive under abnormal growth stimuli and mediates their increased resistance to many chemo-and radiotherapeutic agents. Understanding apoptosis gives a new menu of options for envisioning new strategies for inducing cancer cells to commit suicide. RNAi can be used to increase the apoptotic susceptibility of cancer cells by inhibiting antiapoptotic genes such as bcl-2, livin or survivin (Table 1) . In esophageal adenocarcinoma, the levels of the apoptosis-resistant determinant BCL-XL are dangerously high. A 50% decrease in protein expression was reported using RNAi against BCL-XL mRNA. 88 In Hela cells, silencing of livin strongly increased the apoptotic rate in response to different proapoptotic stimuli. 89 survivin should also be considered a good target because of its precise cell-cycle-dependent expression at mitosis, and its exclusivity for tumor cells. [90] [91] [92] A tumor is unable to grow above a few mm 3 in size without development of a new blood supply. The transition from dormant to active vascularization is not yet totally understood, but the process is most likely triggered when hypoxia around the tumor leads to the expression of hypoxia response genes, such as vascular endothelial growth factor A (VEGF-A) and placenta growth factor, which specifically stimulate the growth of endothelial cells. As most experts believe that drugs specifically targeting the growth of endothelial cells, rather than cancer cells themselves, are least likely to cause resistance, several endogenous inhibitors (endostatin, thrombospondin-1, angiostatin) and many synthetic inhibitors (TNP-470, squalamine, IM-862, combretastatin, thalidomide, SU5416, EMD121974, LY317615) against angiogenesis were used over the past 10 years. 93, 94 However, cancer cells seem to find it easy to get around the blockage of one angiogenic pathway, and clinical trials of the inhibitory drugs have so far fallen short of expectations. 94, 95 On the other hand, the combination of more than one antiangiogenic agent can produce a synergistic effect that might keep tumors under control. The antiangiogenic molecule thrombospondin-1 reduces vascularization and delays tumor development. Yet over time, tumor cells producing active thrombospondin-1 secrete unusually high amounts of VEGF that eventually enable tumors to bypass growth arrest. 96 However, when tumor cells producing thrombospondin-1 under the control of a tetracycline promoter are transfected with siRNA against VEGF, and then injected into nude mice, an 86% reduction of tumor volume was observed when compared to the control group. 97 Also, siRNAs are small in size and it is possible to include more than one antiangiogenic siRNA into a single retroviral vector, which could inhibit multiple pathways simultaneously. Some problems may arise, however, if two promoters are physically close such as competitive interference, promoter suppression and rearrangements. [98] [99] [100] [101] [102] Another complicated task to deal with in cancer is the metastatic process. The characterization of new genes differentially expressed in metastatic cancers can help to discover important mechanisms involved in the metastatic phenotype. However, numerous alterations are very likely needed to allow a tumor cell to become metastatic, and it is not always easy to distinguish the essential genes in the process. Expression profiling, comparing melanoma variants with low or high metastatic potential using cDNA and microarrays, has allowed the identification of the small GTPase RhoC (Table 1) as a putative RNAi target to inhibit metastases. 103 In a similar way, cDNA microarrays have been used to detect gene expression differences between some common cancers (breast, lung and renal) and normal tissues. In addition to already known tumor-associated genes, novel targets for tumor therapy have been identified in this way, such as genes involved in bone matrix mineralization (osn, opn and osf-2) or genes controlling Ca 2 þ homeostasis (rcn1, calca) among others. 104 Toxins have been used in the past to target the neoplastic cell. 105, 106 Retroviral vectors have been constructed, in which a toxin gene, the Pseudomonas exotoxin, was placed under the control of the thyroid hormone (T 3 ) regulatable promoter of the rat myelin basic protein. 107 However, the in vitro culture of such retroviral producer cells is always problematic because toxin synthesis must be turned off completely while the retroviral promoters should remain active. Cells in which a complete repression of the toxin is not achieved will die in culture, and long-term culture of the infected cells will tend to favor the selection of mutations in the toxin gene. The combination of a regulatable promoter and siRNA against a toxin gene may improve substantially the production of a sufficient number of lethal retroviruses to be therapeutically acceptable. The two most widely used inducible mammalian systems use tetracycline-or ecdysone-responsive transcriptional elements. 108, 109 Inducible shRNA expression based on the tetracycline repressor and RNA polymerase-III promoters (U6 and 7SK) has been described recently. 110 Human prostate cancer cells (PC-3) exhibited conditional expression of both phosphatidylinositol 3-kinase catalytic subunits (p110a and p110b) due to the expression of corresponding shRNAs. Nevertheless, when the system was applied in vivo to a mouse model for metastatic human prostate cancer, some leakiness in the Dox-controlled shRNA expression was observed. Stable, inducible and reversible suppression of the green fluorescence protein and human p53 gene was achieved in murine and human cultured cells using an ecdysone-inducible synthesis of shRNAs under the control of a modified U6 promoter. 111 This regulatable promoter could be a better choice than the tetracycline-inducible system, where relative high
The use of RNAi against cancer M Izquierdo backgrounds of expression are not uncommon in the uninduced state in several cell lines 112 and in vivo. 110 The presence of a reliable inducible promoter controlling siRNA production is an important step forward not only for safety reasons but also because it opens the possibility to develop true tissue-specific promoters or even cancer cell-associated promoters in the near future.
There are potential advantages of local gene therapy over systemic drug treatments: no resistance has been described against nucleic acid therapeutic agents in the multiple clinical trials already accomplished; a single treatment should provide enough therapeutic genes to carry out the eradication of the tumor, and therefore a significant cost reduction is expected. Also, the use of siRNAs as a lethal weapon against the cancer cell does not envisage many potential side effects. The main advantage over other killer-suicide methods, such as ganciclovir/tk, 113 or linamarase/linamarine, 114, 115 is that it obviates the need for a prodrug to destroy the cancer cell. When the ganciclovir/herpes simplex tk was applied to humans, 116, 117 a vector carrying the killer gene was first inoculated into the tumor of the patient, who 1 week later received the ganciclovir prodrug that would selectively kill the cells able to process it to its toxic derivative. With this two-components system, it is always possible to halt the delivery of the prodrug if it was needed for safety reasons. RNAi, on the other hand, needs a single treatment, and the difficulty of stopping the process once initiated can now be solved with the ecdysone-inducible polymerase-III-specific U6 promoter used in some retroviral vectors and in those mentioned above. 111 RNAi can help in the identification of ''synthetic lethals'', a combination of two nonlethal mutations that, together, result in cell death. 118 In general, functional mammalian cancer genetic screens have expanded markedly, allowing the discovery of new combinations of activating mutations in oncogenes, and loss-of-function mutations in oncosuppressors. These are important for tumor development, angiogenesis, progression, or metastasis (such as adhesion, cell migration or oxygen sensing).
Many studies have proliferated that describe notable success in provoking cancer cell death in culture by siRNA treatments, but very few yet are complemented with the eradication of well-developed tumors in experimental animals, a necessary step before using this technology in human trials. Also, the ability to deliver efficiently sufficient amounts of siRNA to a particular tumor requires refinement before this new technology can be tried clinically. Initial in vivo studies reported effective tumor suppression in nude mice by chemically synthesized siRNAs. More recently, many researchers have used plasmid and viral vectors for transcription of shRNAs, both in vitro and in vivo. With these systems, gene expression was more stably inhibited, but the efficiency of selective delivery will continue to be a limiting factor. Despite all this, there is no doubt that RNAi represents a new front in the war on cancer. Human trials exploiting this powerful technology are likely to follow soon.
